Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA4 | P22748 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.39 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.39 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834073 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL14706787 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL17834047 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL16202805 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL17834048 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL14706769 | 1.00 | CA1 (0.54) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL4839886 | 0.98 | CA1 (0.52) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL4847081 | 0.98 | CA1 (0.52) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL4839021 | 0.95 | CA1 (0.48) | CA1CA2CA4MEN1ALDH1A1 | |
| SCHEMBL20668122 | 0.84 | CA1 (0.39) | CA1CA2CA4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120110900-A1 | Liquid fuel composition and method for enhancing combustion efficiency of a liquid fuel | TSAI KAI-SHON (TW) | 2012-05-10 | — | — | US | claimed |
| WO-2011073843-A1 | ODORANT ALCOHOLS | FIRMENICH SA (CH) | 2011-06-23 | — | — | WO | claimed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-9012497-B2 | Cyclohexyl carbamate compounds as active anti-cellulite ingredients | SYMRISE AG (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE AG (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130137710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS | SYMRISE AG (DE) | 2013-05-30 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | CA1 2719/4885CA2 1934/4885CA4 3899/4885 |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CA1 4071/4885CA2 2496/4885CA4 4166/4885 |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | CA1 2981/4885CA2 2126/4885CA4 4152/4885 |
| US-20130156710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | CBR1, CYP2A13, CBR3 | CA1 2601/4885CA2 929/4885CA4 893/4885 |
| US-20130137710-A1 | CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS | CBR1, NCOR2, CECR2 | CA1 2365/4885CA2 250/4885CA4 400/4885 |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | CA1 1026/4885CA2 2767/4885CA4 1056/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CA1 4071/4885CA2 2496/4885CA4 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.